Novartis multiple sclerosis therapy fingolimod granted FDA Breakthrough Therapy designation for pediatric MS

Novartis multiple sclerosis therapy fingolimod granted FDA Breakthrough Therapy designation for pediatric MS

Dec 18, 2017
Source URL: https://qa1.novartis.us/news/media-releases/novartis-multiple-sclerosis-therapy-fingolimod-granted-fda-breakthrough-therapy-designation-pediatric-ms-0

List of links present in page
  1. https://qa1.novartis.us/news/media-releases/novartis-multiple-sclerosis-therapy-fingolimod-granted-fda-breakthrough-therapy-designation-pediatric-ms-0